Mineralys Therapeutics Share Price Today

Mineralys Therapeutics grants inducement equity awards to new hire

Granted inducement stock options for 14,880 shares and RSUs for 11,160 shares. Awards issued under Nasdaq Listing Rule 5635(c)(4) for a new non-executive employee. Both awards feature a four-year vesting period starting November 2, 2026. Stock options vest 25% initially then monthly; RSUs vest 25% annually.

Mineralys Therapeutics Q3FY27 Results: Net loss widens to $57.3 million

Net loss widened to $57.3 million in Q3 2026 from $36.9 million in Q3 2025. Cash position stands at $624.7 million, funding operations into 2028. G&A expenses surged to $37.4 million due to commercialization efforts. R&D expenses declined to $22.7 million as pivotal trials concluded.

Mineralys Therapeutics appoints Peterson and Coats to board

Mineralys Therapeutics appointed Kristine Peterson and Lonnel Coats to its Board of Directors on October 19, 2026. The appointments support the potential commercial launch of lorundrostat for uncontrolled hypertension. Peterson brings over 30 years of biopharma experience, including roles at Johnson & Johnson and Bristol-Myers Squibb. Coats has over 30 years of experience leading commercial organizations, previously serving as CEO of Lexicon Pharmaceuticals.

Mineralys Therapeutics to present lorundrostat CKD data at ASN Kidney Week

Mineralys Therapeutics will present new Launch-HTN trial data at ASN Kidney Week 2026 in Denver, Colorado. The presentation covers blood pressure and albuminuria reduction in chronic kidney disease stages 1 to 3. Dysregulated aldosterone drives hypertension in approximately 30% of all hypertensive patients. Less than 50% of hypertensive patients achieve blood pressure goals with current medications.

Mineralys to present lorundrostat data at AHA hypertension sessions

Mineralys Therapeutics will present five abstracts on lorundrostat at the AHA Hypertension Scientific Sessions 2026. An oral presentation on October 8 will cover Explore-OSA trial results for obstructive sleep apnea and hypertension. Four poster sessions on October 9 will address Launch-HTN responder analysis, cardiorenal injury, and real-world data. The Launch-HTN Phase 3 trial evaluated lorundrostat in adults with uncontrolled or resistant hypertension.

Mineralys Therapeutics grants inducement equity awards to new hires

Mineralys Therapeutics granted inducement equity awards to two new non-executive employees on September 28, 2026. The package includes options for 46,430 shares and RSUs for 34,823 shares, totaling 81,253 shares. Options vest 25% at one year with monthly vesting thereafter; RSUs vest 25% annually over four years. Awards were issued under Nasdaq Listing Rule 5635(c)(4) as a material inducement for hiring.